CURIA-TOUCHLIGHT ALLIANCE EXPANDS BIOLOGICS CAPABILITIES WITH ACCESS TO ENZYMATIC DOGGYBONE DNA

KUALA LUMPUR, July 25 (Bernama) -- Curia, a contract research, development and manufacturing organisation, and Touchlight, a company pioneering enzymatic DNA production, announced an agreement which will provide Curia and its clients a streamlined means of access to Touchlight’s doggybone DNA (dbDNA).

The arrangement expands Curia’s messenger ribonucleic acid (mRNA) manufacturing offerings with an additional differentiated source of DNA raw material that is immediately available to be accessed by Curia customers, while Touchlight will directly manufacture dbDNA on behalf of Curia’s customers.

“Curia remains committed to strengthening our biologics offerings and end-to-end mRNA manufacturing capabilities.

“With the addition of enzymatic DNA through our partnership with Touchlight, our customers will have a critical advantage in terms of scalability and speed to market,” said Curia President of R&D, Christopher Conway in a statement.

Meanwhile, Touchlight Chief Executive Officer, Karen Fallen said: “We are delighted to work with Curia in order to further expand access to dbDNA as a critical starting material.

“Curia is building a comprehensive mRNA solution, and this arrangement enables both companies to extend their offering to a wider audience.”

Touchlight’s dbDNA is a linear, double-stranded, covalently-closed DNA vector. DNA serves as the template for making mRNA therapies, and via a simple enzymatic process called in vitro transcription, genetic information is copied from DNA to mRNA.

This mRNA is then able to teach the cells to make precise proteins that are used to treat or prevent diseases. Touchlight’s enzymatic DNA is produced with a cell-free enzymatic process that offers unmatched benefits in speed, quality and capacity when compared to traditional plasmid DNA production.

-- BERNAMA